Antibody recycling via FcRn drives atherosclerotic plaque vulnerability

This study demonstrates that FcRn-mediated recycling of apoB-specific IgG antibodies by macrophages drives atherosclerotic plaque vulnerability through increased inflammation and extracellular matrix degradation, identifying FcRn as a promising therapeutic target.

The Gist

The Big Picture: A Traffic Jam in Your Arteries

Imagine your arteries are like busy highways. Over time, "gunk" (cholesterol and fats) starts to pile up on the sides, creating traffic jams called atherosclerotic plaques.

Most of the time, these jams are stable. But sometimes, the road barrier (the "fibrous cap") gets thin and weak, causing the traffic jam to burst open. When that happens, it causes a heart attack or a stroke. Scientists call this a "vulnerable plaque."

This study asks a simple question: Why do some of these traffic jams become unstable and dangerous while others stay safe?

The Cast of Characters

1. The Gunk (LDL/ApoB): The cholesterol that builds up the plaque.
2. The Security Guards (Antibodies/IgG): Your body sends special proteins called antibodies to try to clean up the gunk. Think of them as police officers trying to arrest the bad guys.
3. The Recycling Plant (FcRn): This is the star of the show. It's a machine inside the cells that usually saves antibodies from being thrown away, recycling them so they can keep working.
4. The Demolition Crew (Macrophages): These are immune cells that eat the gunk. Sometimes, they get too excited and start tearing down the road barriers (the fibrous cap).

The Discovery: The "Recycling Loop" Gone Wrong

The researchers found something surprising happening inside the dangerous, unstable plaques:

1. The Security Guards are Overworked
In dangerous plaques, there are huge amounts of antibodies (IgG) stuck to the cholesterol gunk. Normally, your body would clean these up. But in these plaques, the Recycling Plant (FcRn) is working overtime.

2. The "Salvage" Effect
Think of the Recycling Plant (FcRn) as a very efficient "Save Button." Instead of letting the antibodies get destroyed after they do their job, this machine grabs them, cleans them off, and sends them back out to fight again immediately.

• The Problem: In a healthy plaque, this is fine. But in a dangerous plaque, the machine is stuck in "Recycle Mode." It keeps the antibodies trapped in the area, constantly re-attacking the gunk.

3. The Demolition Crew Gets Angry
Because the antibodies are being recycled so aggressively, the "Demolition Crew" (macrophages) gets super stimulated. They start acting like angry construction workers who aren't just cleaning up; they are also tearing down the walls.

• They release chemicals (like MMP-9 and TNF) that dissolve the collagen holding the plaque together.
• This makes the "fibrous cap" (the road barrier) paper-thin.

4. The Result: A Ticking Time Bomb
The more the Recycling Plant works, the more the Demolition Crew tears down the barrier. Eventually, the plaque bursts, causing a heart attack.

The "Symptomatic" Clue

The researchers looked at patients who had recently had symptoms (like a mini-stroke) versus those who didn't.

• Symptomatic patients had plaques where the antibodies were being recycled faster than usual.
• They had less of the "waste" (immune complexes) because the Recycling Plant was so efficient at grabbing them and sending them back out to cause more inflammation.
• It's like a factory that is so good at reusing parts that it never lets the waste pile up, but in doing so, it keeps the machines running at a dangerous, overheating speed.

The Solution: Hitting the "Pause" Button

The most exciting part of the study is the potential cure. The researchers tested a drug (rozanolixizumab) that is already used for other diseases. This drug acts like a brake on the Recycling Plant.

• In the lab: When they blocked the Recycling Plant, the antibodies stopped getting recycled.
• The Result: The Demolition Crew calmed down. They stopped producing the chemicals that dissolve the plaque walls. The inflammation went down, and the plaque became more stable.

The Takeaway

This study suggests that atherosclerosis isn't just about cholesterol; it's about how your body handles its own immune system.

In dangerous plaques, a specific machine (FcRn) is stuck in "high-recycle" mode, keeping inflammatory antibodies active and angry. This causes the plaque to crumble. By using a drug to block this machine, we might be able to stop the plaque from bursting, effectively turning a ticking time bomb back into a stable traffic jam.

In short: The body's attempt to clean up the mess is actually making the mess worse by recycling the cleanup crew too efficiently. Stopping the recycling might save the road.

Technical Summary

1. Problem Statement

Atherosclerosis is a chronic inflammatory disease characterized by the accumulation of apolipoprotein B (apoB)-containing lipoproteins (LDL) in arterial walls. While the role of lipids is well-established, the precise contribution of the adaptive immune system—specifically antibodies targeting apoB—to plaque destabilization and rupture remains unclear.

• The Gap: Atherosclerotic plaques contain abundant immunoglobulins (IgG, IgM, IgA), but it is unknown whether these antibodies are locally produced or transported from the plasma, how they interact with plaque cells, and whether specific mechanisms (like antibody recycling) drive the transition from stable to vulnerable (rupture-prone) plaques.
• Hypothesis: The authors hypothesized that apoB-specific immune complexes actively promote plaque destabilization through a mechanism involving the neonatal Fc receptor (FcRn), which mediates antibody recycling and amplifies local inflammation.

2. Methodology

The study employed a multi-faceted approach combining human clinical samples, ex vivo tissue culture, and in vitro cell models:

• Human Cohort: Analysis of carotid endarterectomy specimens from the BiKE biobank (symptomatic and asymptomatic patients) and non-diseased iliac artery controls.
• Histopathology & Imaging:
  • Immunohistochemistry (IHC) and immunofluorescence to quantify deposition of IgG, IgA, IgM, and IgE across plaque regions (fibrous cap, shoulder, necrotic core).
  • Morphological assessment of fibrous cap thickness, collagen content, and necrotic core size.
  • Computed Tomography Angiography (CTA) for in vivo plaque vulnerability indices.
• Molecular Profiling:
  • ELISA to measure antibody isotypes, apoB levels, and apoB-IgG immune complexes in plaque homogenates and matched plasma.
  • Integration of single-cell RNA sequencing (scRNA-seq) and single-cell ATAC-seq datasets to identify cell-specific expression of FCGRT (the gene encoding FcRn).
• In Vitro Models:
  • Macrophage Assays: Used RAW 264.7 (mouse) and THP-1 (human) macrophages.
  • Interventions: FcRn knockdown (siRNA) in mouse cells; treatment with rozanolixizumab (a clinically approved anti-human FcRn monoclonal antibody) in human cells.
  • Stimuli: Immune complexes formed by incubating isolated IgG (from plaques or transgenic mice) with oxidized LDL (oxLDL).
• Ex Vivo Culture: Fresh human carotid plaque fragments were cultured with LPS and treated with rozanolixizumab to measure cytokine and enzyme secretion.

3. Key Contributions

1. Mapping the Immunoglobulin Landscape: Demonstrated that IgG and IgM are the dominant immunoglobulins in plaques, primarily localized in the necrotic core and shoulder regions, rather than the fibrous cap.
2. Source Identification: Showed that local B-cell production is negligible; plaque antibodies are largely derived from systemic circulation via transcytosis or transudation.
3. Mechanistic Discovery: Identified FcRn (expressed predominantly by CD163+ resident-like macrophages) as the driver of IgG recycling within the plaque, rather than just a passive transporter.
4. Therapeutic Validation: Proved that blocking FcRn with a clinically used antibody (rozanolixizumab) reduces inflammatory cytokine production and matrix degradation in human plaque tissue.

4. Key Results

• IgG Correlates with Vulnerability:

  • IgG deposition was strongly associated with thin fibrous caps, reduced collagen, and higher vulnerability indices.
  • IgG-rich plaques had significantly thinner caps and larger lipid-rich necrotic cores compared to IgG-poor plaques.
  • IgG levels did not correlate with traditional risk factors (age, BMI, lipids) but did correlate with local inflammatory markers (NLRP3, T-cells).

• Dynamic ApoB-IgG Immune Complex Turnover:

  • Symptomatic patients exhibited higher levels of free anti-apoB IgG but lower levels of apoB-IgG immune complexes within the plaque compared to asymptomatic patients.
  • This suggests enhanced uptake and recycling of immune complexes by plaque cells in symptomatic cases, leading to the depletion of detectable complexes and accumulation of free IgG.

• FcRn Expression and Macrophage Phenotype:

  • FCGRT mRNA was upregulated in carotid plaques compared to healthy arteries.
  • FcRn protein was localized to CD163+ macrophages in the plaque shoulder.
  • The population of FcRn+ macrophages expanded with age and correlated with markers of instability (MMP-9, TNF, IL-1β).

• Functional Role of FcRn (In Vitro & Ex Vivo):

  • Recycling & Uptake: FcRn mediates the recycling of anti-apoB IgG and facilitates the uptake of LDL-IgG immune complexes by macrophages.
  • Inflammation: FcRn signaling drives the production of TNF, IL-1β, and MMP-9 (a key enzyme that degrades the fibrous cap).
  • Intervention: Treatment with rozanolixizumab (FcRn blocker) significantly reduced IgG recycling, suppressed TNF and MMP-9 secretion, and decreased LDL uptake in both human macrophages and ex vivo plaque cultures.

5. Significance and Implications

• Novel Pathogenic Mechanism: The study establishes a causal link between FcRn-dependent antibody recycling and plaque vulnerability. It suggests that the "recycling" of IgG by macrophages prevents antibody degradation, prolonging their presence in the plaque and sustaining inflammatory signaling (TNF/IL-1β) and matrix destruction (MMP-9).
• Therapeutic Target: FcRn is a validated drug target (already approved for Generalized Myasthenia Gravis). The findings suggest that FcRn blockade could be repurposed to stabilize atherosclerotic plaques by reducing local inflammation and preventing fibrous cap thinning.
• Precision Medicine Potential: The study proposes that plaques could be stratified as "IgG-rich" (high risk) vs. "IgG-poor" (lower risk), potentially guiding the use of FcRn inhibitors for patients with high-risk, antibody-driven inflammation.
• Age-Related Progression: The age-associated expansion of FcRn+ macrophages provides a mechanistic explanation for why atherosclerosis becomes more unstable and symptomatic in older populations.

In conclusion, the paper redefines the role of antibodies in atherosclerosis from passive markers to active drivers of plaque rupture via FcRn-mediated recycling, offering a promising new avenue for therapeutic intervention.